| 08:00 | Registration | |
|---|---|---|
| Opening remarks | ||
| 09:00 | Opening and introductions | Board stichting NCHIV |
| SESSION 1: Challenges to silencing the virus | ||
| Chairs: Shringar Rao (Erasmus MC) and Casper Rokx (Erasmus MC) | ||
| 09:10 - 09:35 | Plenary: Host and viral factors underlying HIV elite control: implications for approaches to cure | Prof. Mathias Lichterfeld (Harvard Medical School, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, USA) |
| 09:35 - 09:50 | Moderated Q&A | |
| 09:50 - 10:00 | O.01: Abortive HIV RNA in serum inversely correlates with transcriptional activity of the HIV reservoir in People with HIV | Stefanie Kroeze (Amsterdam UMC) |
| 10:00 - 10:10 | O.02: Starting ART early after HIV acquisition reduces long-term Non-AIDS Defining Malignancy risk | Iris van der Wulp (Amsterdam UMC) |
| 10:10 - 10:20 | O.03: Targeting Host Factors DDX3 and IAP Eliminates the HIV-1 Reservoir in People Living with HIV ex vivo | Jade Jansen (Amsterdam UMC) |
| 10:20 - 10:30 | O.04: Exploring and comparing Biomarker Profiles and Comorbidity burden in people with and without HIV: A Latent Profile Analysis of the AGEhIV Cohort Study | Manon Vanbellinghen (Amsterdam UMC) |
| 10:30 | Refreshment break | |
| SESSION 2: Overcoming health disparities | ||
| Chairs: Anders Boyd (SHM, GGD Amsterdam) and Sarah Stutterheim (Maastricht University) | ||
| 11:00-11:35 | SHM 2023 Monitoring Report key findings presentation - Demo: Mapping HIV | Ard van Sighem (SHM) Vita Jongen (SHM) Rosan van Zoest, (Amsterdam health & technology institute, Ahti) |
| 11:35-11:45 | O.05: Barriers and missed opportunities in PrEP uptake, use and care among MSM with recent HIV infection and previous PrEP experience in the Netherlands, 2022-2023: a qualitative study | Jeffrey Koole (GGD Amsterdam) |
| 11:45-11:55 | O.06: Unmasking HIV stigma: Perspectives of Dutch healthcare providers | Carlijn Jordans (Erasmus MC) |
| 11:55-12:20 | Plenary: Engaging the "Social" in HIV Research: Science & Community | Prof. Judith D. Auerbach (University of California, San Francisco, USA) |
| 12:20-12:30 | Moderated Q&A | |
| 12:30-14:00 | Lunch and poster presentations | |
| SESSION 3: Present and future of HIV and STI prevention | ||
| Chairs: Monique Nijhuis (UMC Utrecht) Henry de Vries (Amsterdam UMC, GGD Amsterdam) | ||
| 14:00-14:25 | Plenary: Current and future options for biomedical prevention of HIV and STIs (online) | Prof. Jean-Michel Molina (University of Paris Diderot, Saint-Louis Hospital, Paris, France) |
| 14:25-14:35 | Moderated Q&A | |
| 14:35-14:50 | O.07: STI testing rates among PrEP users randomized to receiving 3-monthly or 6-monthly PrEP monitoring within the EZI-PrEP trial, the Netherlands: preliminary results | Marije Groot Bruinderink (GGD Amsterdam) |
| 14:50-15:00 | O.09: BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted is well-tolerated, has acceptable safety profile and elicits a potent autologous serum antibody response in HIV-uninfected adults in good general health | Karlijn van der Straten (Amsterdam UMC) |
| 15:00-15:10 | O.10: BG505 SOSIP.GT1.1 gp140 expands B cells with broadly neutralizing antibody signatures: preliminary results from a phase 1 human clinical trial | Tom Caniels (Amsterdam UMC) |
| 15:10-15:20 | O.11: Membrane-bound germline-targeting HIV-1 Env immunogens for mRNA vaccination | Iván Del Moral-Sánchez (Amsterdam UMC) |
| 15:20-15:30 | O.08: Sex-based differences in autologous neutralising antibody responses induced by a native-like HIV-1 envelope trimer vaccine | Emma Reiss (Amsterdam UMC) |
| 15:30 | Refreshment break | |
| SESSION 4: Ratatouille of topics | ||
| Chairs: Vanessa Harris (Amsterdam UMC) and Natasja van Holten (LUMC) | ||
| 16:00-16:10 | O.12: One-year evaluation: low acceptance and increasing costs following a health insurer-mandated split from branded single-tablet regimen to generic-based two-tablet regimen | Piter Oosterhof (OLVG, Radboudumc) |
| 16:10-16:20 | O.13: Majority of infected cells from peripheral blood of ART-treated individuals transcribe HIV-1 cell-associated gag RNA | Alexander Pasternak (Amsterdam UMC) |
| 16:20-16:30 | O.14: Implementing HIV teams sustainably improves HIV testing rates in patients with HIV indicator conditions: a multicenter study | Klaske Vliegenthart-Jongbloed (Erasmus MC) |
| Unique aspects of Cardiovascular Disease among Women with HIV: lessons from REPRIEVE | ||
| 16:30-16:45 | Introduction (online) | Dr. Markella Zanni (Dept of endocrinology, Mass General Hospital, Boston, USA) |
| 16:45-17:20 | Panel discussion: Cardiovascular Disease Pathogenesis and Prevention: should we think differently about women with HIV? | Hester den Ruijter, Berend van Welzen Fanny Lauw, Markella Zanni, Natasja van Holten, Vanessa Harris (moderator) |
| 17:20 | Presentation of Joep Lange & Jacqueline van Tongeren Junior Investigator’s Award and Best Poster Award winners & Closing | |
| Board stichting NCHIV | ||
| 17:30 | Drinks | |
Programme 2023
NCHIV is organised by
